

United States Patent and Trademark Office

CNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/020,747	11/30/2001	Tiecheng A. Qiao	82429D-W	9726
7	590 12/01/2003		EXAM	INER
Paul A. Leipold			BISSETT, MELANIE D	
Patent Legal St Eastman Kodal			ART UNIT	PAPER NUMBER
343 State Street			1731	
Rochester, NY 14650-2201			DATE MAILED: 12/01/200	3

Please find below and/or attached an Office communication concerning this application or proceeding.

· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)
	10/020,747	QIAO ET AL.
Office Action Summary	Examiner	Art Unit
	Melanie D. Bissett	1711
The MAILING DATE of this communication a	appears on the cover sheet wi	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is tess than thirty (30) days, a - If NNO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by sta - Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b). Status	N. 1.136(a). In no event, however, may a reply within the statutory minimum of third od will apply and will expire SIX (6) MON tute, cause the application to become AE	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED, (35 U.S.C. § 133).
1) Responsive to communication(s) filed on 04	September 2003.	
2a)⊠ This action is FINAL. 2b)☐ Th	nis action is non-final.	
Since this application is in condition for allow closed in accordance with the practice under the condition of the condi		
Disposition of Claims		
4)⊠ Claim(s) <u>1-12 and 14-20</u> is/are pending in th	• •	
4a) Of the above claim(s) is/are withd	rawn from consideration.	
5)⊠ Claim(s) <u>1-12 and 15</u> is/are allowed.		
6)⊠ Claim(s) <u>16-20</u> is/are rejected. 7)⊠ Claim(s) <u>14</u> is/are objected to.		
8) Claim(s) are subject to restriction and	d/or election requirement.	
Application Papers	aron orocaon roquii ornona.	
	lo a r	
9) The specification is objected to by the Exam 10) The drawing(s) filed on is/are: a)		by the Examiner
Applicant may not request that any objection to t	• •	•
Replacement drawing sheet(s) including the corr		
11) The oath or declaration is objected to by the		
Priority under 35 U.S.C. §§ 119 and 120		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of:	eign priority under 35 U.S.C.	§ 119(a)-(d) or (f).
1. Certified copies of the priority docume	ents have been received.	
2. Certified copies of the priority docume		
3. Copies of the certified copies of the p application from the International Bur		received in this National Stage
* See the attached detailed Office action for a l	ist of the certified copies not	
13) Acknowledgment is made of a claim for dome since a specific reference was included in the 37 CFR 1.78.		
a) The translation of the foreign language		
14) Acknowledgment is made of a claim for dome reference was included in the first sentence of	estic priority under 35 U.S.C. f the specification or in an Ap	§§ 120 and/or 121 since a specific plication Data Sheet, 37 CFR 1.78.
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s	5) Notice of I	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)
Sy R S Simulation District Controlled (1) 10 11 10/1 apor 110/2	,	

Art Unit: 1711

 The rejections based on 35 USC 103 have been maintained in part and withdrawn in part based on the applicant's amendments.

Claim Objections

2. Claim 14 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 12 has been amended to include the limitation that the ALB compound is affixed *while* coating the gelatin on the substrate. However, claim 14 states that the ALB compound is affixed *after* coating gelatin on the substrate. Therefore, the contradiction between claim 14 and claim 12 prevents claim 14 from further limiting claim 12.

Claim Rejections - 35 USC § 103

- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. Claims 16-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Zyomyx, Inc. in view of Marks et al.
- From a prior Office action:
 - 3. Zyomyx discloses protein arrays comprising a substrate, an organic thin film, and proteins immobilized on the thin film (p. 5 lines 6-12). The substrates may be coated before the addition of the organic thin film (p. 19 lines 20-29), where the organic thin film is preferably a monolayer having the formula X-R-Y which fits the applicant's trifunctional compound (p. 22 lines 8-20). The linking group R preferably comprises an alkyl chain having from 8-22 carbons, suggesting through-bond paths connecting the functional groups of not greater than 10 atoms (p. 25 line 27-

Art Unit: 1711

p. 26 line 5). The functional group X interacts with the substrate or coated substrate by chemical or physical means, where X includes isothiocyanate and isocyanate groups (p. 26 lines 14-22). Functional group Y interacts with a protein by covalent or non-covalent finkage, where Y includes aldehydes, maleimides, iodoacetyl, hydrazide, epoxy, aziridine, vinylsulfone, isothiocyanate, and isocyanates groups (p. 28 line 9-p. 29 line 9). Additionally, an affinity tag attached to the Y functional group include glutathione S-transferase or streptavidin groups (p. 33 lines 19-21). Antibodies, known protein capture agents, are noted as proteins to be immobilized on the thin film (p. 33 lines 1-11). A plurality of proteins are attached to different patches on the substrate (p. 5 lines 1-25). However, the reference does not point to gelatin as a coating substance for the substrates. Marks teaches protein assays using coated substrates, teaching the conventionality of coating gelatin on substrates to reduce non-specific binding (col. 32 line 59-col. 33 lines 5; col. 33 lines 39-43). Such coatings also simplify covalent conjugation and enhance signal detection. Because Zyomyx is also concerned with non-specific binding (p. 12 lines 17-19), it is the examiner's position that it would have been prima facie obvious to include a gelatin on Zyomyx's substrate to reduce non-specific binding, simplify covalent conjugation, and enhance signal

4. Regarding the coating coverage of gelatin on the substrate, it is the examiner's position that it would have been prima facie obvious to coat any amount necessary to optimize the non-specific binding, covalent conjugation, and signal detection properties of the coating.

Allowable Subject Matter

- 6. Claims 1-12 and 15 are allowed.
- 7. From a prior Office action:

The closest prior art, Zyomyx, discloses a method of making a protein array, where a coating is deposited or formed prior to the formation of an organic thin film that fits the applicant's formula of claim 12. The coating methods employed do not suggest the simultaneous formation coating of the gelatin and organic thin film layers, and the reference does not suggest the blending of the coating and organic thin film layers. It is the examiner's position that the applicant's claimed method, including the simultaneous coating of gelatin and trifunctional compound, would provide a novel and unobvious step over the prior art.

Response to Arguments

8. In response to the applicant's arguments that the present invention does not consist of patches on a surface but instead is drawn to a continuous coating, it is noted

Art Unit: 1711

that the claims do not exclude patches of coating. The claims simply call for a support having two components coated thereon. Also, it could be argued that a patch is a continuous coating to the extent that the patch is coated.

- Regarding the arguments that the present invention coats the ALB component with the gelatin, note that all pending rejections are drawn to claims that do not specify such a limitation.
- 10. Regarding the applicant's arguments that Marks et al. does not teach the coating of gelatin on the substrate for a protein array, it is noted that the reference specifically teaches preparing a surface of a substrate by coating it with gelatin (col. 33 lines 39-44). The substrates noted in Marks encompass the same as those noted in Zyomyx, Inc. Both references teach the formation of a capture agent on a substrate. It is the examiner's position that the references have been properly combined, and the rejection is maintained. Note that the reference cited by the applicant "Elisa: Theory and Practice" is not of record.

Conclusion

11. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Art Unit: 1711

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melanie D. Bissett whose telephone number is (703) 308-6539 or (571) 272-1068 after December 2003. The examiner can normally be reached on M-F 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Seidleck can be reached on (703) 308-2462. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0661.

RABON SERGENT PRIMARY EXAMINER

mdb